Jentadueto helps patients to control their blood sugar. It can be taken twice daily and combines two diabetes medicines – the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin and metformin – in one tablet.
The U.S. Food and Drug Administration (FDA) has approved Jentadueto on 30 January 2012, as a prescription medicine used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate.
Jentadueto cannot be used for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine) and it has not been studied in combination with insulin.
Boehringer Ingelheim Pharmaceuticals vice president of cardiovascular and metabolic disorders marketing David Pass said by combining two important diabetes medicines in a single tablet, Jentadueto provides people with type 2 diabetes another option to control their blood sugar
"Making JENTADUETO available quickly following its approval further demonstrates Boehringer Ingelheim and Lilly’s shared commitment to address the needs of the millions of Americans living with type 2 diabetes," Pass said.